Shine-On Bio Business Summary

Shine-On BioMedical Co., Ltd. (6926.TWO) is a clinical-stage biotechnology firm specializing in the research, development, and manufacturing of next-generation anti-cancer therapeutics. The company’s revenue model is primarily driven by technology licensing, milestone payments, and strategic R&D collaborations, exemplified by its NT$200 million licensing agreement with Singapore-based Esco Aster for its exosome drug delivery platform. Shine-On’s business is segmented into two core technology pillars: trispecific antibodies (SOA series) and engineered exosome-based drug delivery systems (SOB series). Its lead candidate, SOA101, is a first-in-class trispecific antibody targeting advanced solid tumors currently in Phase I trials, while its SOB100 exosome platform is being developed for targeted small-molecule delivery. Within the competitive landscape of Taiwan’s regenerative medicine and oncology sectors, Shine-On competes directly with BRIM Biotechnology (6885.TWSE), BIONET Therapeutics (7808.TPEX), and Libo Pharma (7888.TPEX), distinguishing itself as a pioneer in transitioning exosome-based therapies from cosmetic applications to rigorous clinical oncology. The company was established on April 6, 2021, by its founder, Dr. Chiu-Chin Huang, who serves as a key visionary for the firm’s therapeutic pipeline. The current leadership team is headed by General Manager Hongzhe Jiang (also known as Hung-Che Chiang), who oversees corporate strategy and international licensing efforts. Shine-On’s board and investor base feature prominent institutional backing from major Taiwanese healthcare players, including Center Laboratories, Inc. and Lumosa Therapeutics Co., Ltd., alongside strategic shareholders such as Changjia Intelligent Technology and Tianyue Industrial. This pedigree of investors provides the company with significant capital stability and industry expertise as it advances its multi-target exosome and trispecific antibody platforms through global clinical trials.